Precigen, Inc.
PAPZIMEOS
Recurrent Respiratory Papillomatosis (RRP)
Resolved
7days ago
Phase 1 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 1 trial results for PAPZIMEOS in Recurrent Respiratory Papillomatosis (RRP) are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“The Company will present updated durability of response data at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 29 to June 2, 2026, with a presentation titled “ Zopapogene imadenovec”